| (Values in U.S. Thousands) | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 |
| Sales | 10 | 10 | 10 | 0 | 10 |
| Sales Growth | unch | unch | unch | -100.00% | unch |
| Net Income | -3,860 | -2,090 | -3,470 | -2,960 | -3,600 |
| Net Income Growth | -84.69% | +39.77% | -17.23% | +17.78% | -6.19% |
Histogen Inc (HSTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Histogen Inc. is a regenerative medicine company. It engages in developing patented technologies which replace and regenerates tissues in the body. The company's technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products. Histogen Inc., formerly known as Conatus Pharmaceuticals Inc., is based in San Diego, United States.